AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced that the Company will present ...
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
VANCOUVER, British Columbia —
financialpost.com
December 8, 2025 at 9:56 PM
A UBC spin-off headed by Drs. Veronique Lecault and Carl Hansen is helping to bring BC's life science economy forward.
Learn how AbCellera got started in #AntibodyTherapies, growing from six scientists to 600: https://bit.ly/4rnwMvQ
#VancouverBiotech
Learn how AbCellera got started in #AntibodyTherapies, growing from six scientists to 600: https://bit.ly/4rnwMvQ
#VancouverBiotech
December 4, 2025 at 4:49 PM
A UBC spin-off headed by Drs. Veronique Lecault and Carl Hansen is helping to bring BC's life science economy forward.
Learn how AbCellera got started in #AntibodyTherapies, growing from six scientists to 600: https://bit.ly/4rnwMvQ
#VancouverBiotech
Learn how AbCellera got started in #AntibodyTherapies, growing from six scientists to 600: https://bit.ly/4rnwMvQ
#VancouverBiotech
AbCellera Biologics ($ABCL) reported EPS of -0.19 missing estimate of -0.17 for Q3 2025. Revenue 8.955 Million Vs 6.447734 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
November 6, 2025 at 9:15 PM
AbCellera Biologics ($ABCL) reported EPS of -0.19 missing estimate of -0.17 for Q3 2025. Revenue 8.955 Million Vs 6.447734 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
#ABCL AbCellera Reports Q3 2025 Business Results
https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q3-2025-business-26e175j3h9xp.html
https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q3-2025-business-26e175j3h9xp.html
www.stocktitan.net
November 6, 2025 at 9:05 PM
#ABCL AbCellera Reports Q3 2025 Business Results
https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q3-2025-business-26e175j3h9xp.html
https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q3-2025-business-26e175j3h9xp.html
Leerink Partners肯定AbCellera Biologics转型后的增长潜力，维持跑赢大盘评级
https://qian.cx/posts/1C7E4F6B-CF11-4F53-A7C5-54C7096C59EC
https://qian.cx/posts/1C7E4F6B-CF11-4F53-A7C5-54C7096C59EC
November 1, 2025 at 3:07 PM
Leerink Partners肯定AbCellera Biologics转型后的增长潜力，维持跑赢大盘评级
https://qian.cx/posts/1C7E4F6B-CF11-4F53-A7C5-54C7096C59EC
https://qian.cx/posts/1C7E4F6B-CF11-4F53-A7C5-54C7096C59EC
Resist with your Retirement
:Part 1
Some of these are duplicates, but I want you to see the financial overlap.
Peter Thiel
• Palantir Technologies (PLTR)
• Meta (META)
• AbCellera Biologics (ABCL)
• BlackSky Technology (BKSY)
• Affirm Holdings (AFRM)
• Oscar Health (OSCR)
• PayPal (PYPL)
:Part 1
Some of these are duplicates, but I want you to see the financial overlap.
Peter Thiel
• Palantir Technologies (PLTR)
• Meta (META)
• AbCellera Biologics (ABCL)
• BlackSky Technology (BKSY)
• Affirm Holdings (AFRM)
• Oscar Health (OSCR)
• PayPal (PYPL)
October 16, 2025 at 9:00 AM
Resist with your Retirement
:Part 1
Some of these are duplicates, but I want you to see the financial overlap.
Peter Thiel
• Palantir Technologies (PLTR)
• Meta (META)
• AbCellera Biologics (ABCL)
• BlackSky Technology (BKSY)
• Affirm Holdings (AFRM)
• Oscar Health (OSCR)
• PayPal (PYPL)
:Part 1
Some of these are duplicates, but I want you to see the financial overlap.
Peter Thiel
• Palantir Technologies (PLTR)
• Meta (META)
• AbCellera Biologics (ABCL)
• BlackSky Technology (BKSY)
• Affirm Holdings (AFRM)
• Oscar Health (OSCR)
• PayPal (PYPL)
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced that the Company will participate in...
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
VANCOUVER, British Columbia —
financialpost.com
October 7, 2025 at 8:28 PM
Angermeyer, Gotthardt, Leyck, Eli Lilly, Abcellera, Spendendinner, Maskendeals, Julian Reichelt, Andreas Tandler, Emix oder wie Sarah Bosetti sagt: "Spahn schlägt Social-Media Verbot für Jugendliche vor. Was sagt ihr dazu?"
October 1, 2025 at 5:12 PM
Angermeyer, Gotthardt, Leyck, Eli Lilly, Abcellera, Spendendinner, Maskendeals, Julian Reichelt, Andreas Tandler, Emix oder wie Sarah Bosetti sagt: "Spahn schlägt Social-Media Verbot für Jugendliche vor. Was sagt ihr dazu?"
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thurs...
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
VANCOUVER, British Columbia —
financialpost.com
September 29, 2025 at 8:32 PM
September 24, 2025 at 8:10 AM
#SpahnUntersuchungsausschuss
„Als Gesundheitsminister vergab Spahn den millionenschweren Auftrag an den Pharmakonzern Eli Lilly, mit dem die Firma Abcellera laut offizieller Konzern-Pressemitteilungen bei der Entwicklung und Vermarktung des Corona-Medikaments zusammenarbeitete.“
„Als Gesundheitsminister vergab Spahn den millionenschweren Auftrag an den Pharmakonzern Eli Lilly, mit dem die Firma Abcellera laut offizieller Konzern-Pressemitteilungen bei der Entwicklung und Vermarktung des Corona-Medikaments zusammenarbeitete.“
Jens Spahn sitzt in Talkshows statt vor dem Untersuchungsausschuss
September 22, 2025 at 8:52 AM
#SpahnUntersuchungsausschuss
„Als Gesundheitsminister vergab Spahn den millionenschweren Auftrag an den Pharmakonzern Eli Lilly, mit dem die Firma Abcellera laut offizieller Konzern-Pressemitteilungen bei der Entwicklung und Vermarktung des Corona-Medikaments zusammenarbeitete.“
„Als Gesundheitsminister vergab Spahn den millionenschweren Auftrag an den Pharmakonzern Eli Lilly, mit dem die Firma Abcellera laut offizieller Konzern-Pressemitteilungen bei der Entwicklung und Vermarktung des Corona-Medikaments zusammenarbeitete.“
I too would prefer new defense spending commitments were interpreted broadly to encompass health R&D.
Dunno the AbCellera model (billionaires created via huge IPO of heavily government-subsidized company itself spun off from public university research, whose product is sold to govt for💰💰) is ideal?🤔
Dunno the AbCellera model (billionaires created via huge IPO of heavily government-subsidized company itself spun off from public university research, whose product is sold to govt for💰💰) is ideal?🤔
Opinion: Defence spending must include health spending too
Biotech investment can deliver on Canada’s NATO commitments, protect citizens and drive economic growth
www.theglobeandmail.com
September 2, 2025 at 4:03 PM
I too would prefer new defense spending commitments were interpreted broadly to encompass health R&D.
Dunno the AbCellera model (billionaires created via huge IPO of heavily government-subsidized company itself spun off from public university research, whose product is sold to govt for💰💰) is ideal?🤔
Dunno the AbCellera model (billionaires created via huge IPO of heavily government-subsidized company itself spun off from public university research, whose product is sold to govt for💰💰) is ideal?🤔
"What’s needed now is vision backed by bold action."
Oh, we've got that, we see austerity backed with bold cuts.
Defence spending must include health spending too - The Globe and Mail
https://www.theglobeandmail.com/business/commentary/article-defence-spending-health-abcellera-biotech/ […]
Oh, we've got that, we see austerity backed with bold cuts.
Defence spending must include health spending too - The Globe and Mail
https://www.theglobeandmail.com/business/commentary/article-defence-spending-health-abcellera-biotech/ […]
Original post on mstdn.ca
mstdn.ca
September 2, 2025 at 3:37 PM
"What’s needed now is vision backed by bold action."
Oh, we've got that, we see austerity backed with bold cuts.
Defence spending must include health spending too - The Globe and Mail
https://www.theglobeandmail.com/business/commentary/article-defence-spending-health-abcellera-biotech/ […]
Oh, we've got that, we see austerity backed with bold cuts.
Defence spending must include health spending too - The Globe and Mail
https://www.theglobeandmail.com/business/commentary/article-defence-spending-health-abcellera-biotech/ […]
#ABCL AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
https://www.stocktitan.net/news/ABCL/ab-cellera-doses-first-participants-in-a-phase-1-clinical-trial-of-aubzc332dcv9.html
https://www.stocktitan.net/news/ABCL/ab-cellera-doses-first-participants-in-a-phase-1-clinical-trial-of-aubzc332dcv9.html
6-Month Dosing Breakthrough: AbCellera's New Atopic Dermatitis Drug Begins First Human Trial
AbCellera launches Phase 1 trial of ABCL575, an OX40 ligand-targeting antibody for atopic dermatitis with 6-month dosing interval. Data expected mid-2026.
www.stocktitan.net
August 27, 2025 at 1:00 PM
#ABCL AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
https://www.stocktitan.net/news/ABCL/ab-cellera-doses-first-participants-in-a-phase-1-clinical-trial-of-aubzc332dcv9.html
https://www.stocktitan.net/news/ABCL/ab-cellera-doses-first-participants-in-a-phase-1-clinical-trial-of-aubzc332dcv9.html
Har en liten portfölj jag kallar ”Wild Things” med lite mer…spekulativa aktier. Den är upp 84% i år! Vi ska inte prata om hur det gått tidigare år 😂 Försöker likvidera den, och investera i mer kvalitet, bara tre aktier kvar nu:
Metacon +122% i år.
Abcellera +49%
Nio +44%
#finanstwitter
Metacon +122% i år.
Abcellera +49%
Nio +44%
#finanstwitter
August 25, 2025 at 9:35 AM
Har en liten portfölj jag kallar ”Wild Things” med lite mer…spekulativa aktier. Den är upp 84% i år! Vi ska inte prata om hur det gått tidigare år 😂 Försöker likvidera den, och investera i mer kvalitet, bara tre aktier kvar nu:
Metacon +122% i år.
Abcellera +49%
Nio +44%
#finanstwitter
Metacon +122% i år.
Abcellera +49%
Nio +44%
#finanstwitter
AbCellera Biologics ($ABCL) reported EPS of -0.12 beating estimate of -0.17 for Q2 2025. Revenue 17.084 Million Vs 6.583736 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
August 7, 2025 at 8:37 PM
AbCellera Biologics ($ABCL) reported EPS of -0.12 beating estimate of -0.17 for Q2 2025. Revenue 17.084 Million Vs 6.583736 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
AbCellera Revenue Soars 133% on Licensing Deal as Focus Pivots to Clinical Trials https://signalbloom.ai/news/ABCL/abcellera-revenue-soars-133-on-licensing-deal-as-focus-pivots-to-clinical-trials $ABCL #Earnings via @signalbloom.ai
August 7, 2025 at 8:36 PM
AbCellera Revenue Soars 133% on Licensing Deal as Focus Pivots to Clinical Trials https://signalbloom.ai/news/ABCL/abcellera-revenue-soars-133-on-licensing-deal-as-focus-pivots-to-clinical-trials $ABCL #Earnings via @signalbloom.ai
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) toda...
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
#Business #Wire #News #Releases #PMN #Press #Releases #BW
Origin | Interest | Match
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
VANCOUVER, British Columbia —
financialpost.com
August 7, 2025 at 8:47 PM
AbCellera Biologics Inc.（ABCL）牛市理论详解及未来发展潜力分析
https://qian.cx/posts/A2BFD5B8-499D-4116-A0E9-698159CBCA61
https://qian.cx/posts/A2BFD5B8-499D-4116-A0E9-698159CBCA61
August 2, 2025 at 2:57 AM
AbCellera Biologics Inc.（ABCL）牛市理论详解及未来发展潜力分析
https://qian.cx/posts/A2BFD5B8-499D-4116-A0E9-698159CBCA61
https://qian.cx/posts/A2BFD5B8-499D-4116-A0E9-698159CBCA61
Angermayer, teilt der Anwalt mit, habe nichts mit dem Deal, nichts mit Eli Lilly und auch nur ganz minimal mit Abcellera zu tun gehabt. Er sei nur mit rund zwei Prozent an der Biotech-Firma beteiligt gewesen und sei nie an dem operativen Geschäft beteiligt gewesen. (9/10)
July 23, 2025 at 9:02 AM
Angermayer, teilt der Anwalt mit, habe nichts mit dem Deal, nichts mit Eli Lilly und auch nur ganz minimal mit Abcellera zu tun gehabt. Er sei nur mit rund zwei Prozent an der Biotech-Firma beteiligt gewesen und sei nie an dem operativen Geschäft beteiligt gewesen. (9/10)
Angermayer soll mit seinen Abcellera-Aktien dank des rasanten Kursanstiegs vor dem Börsengang kurz vor dem Deal 100 Millionen eingestrichen haben, berichteten Wirtschaftsmedien. Fragt man heute nach, bekommt man sehr böse Briefe von seinem Anwalt Herrn Höcker. (8/10)
July 23, 2025 at 9:02 AM
Angermayer soll mit seinen Abcellera-Aktien dank des rasanten Kursanstiegs vor dem Börsengang kurz vor dem Deal 100 Millionen eingestrichen haben, berichteten Wirtschaftsmedien. Fragt man heute nach, bekommt man sehr böse Briefe von seinem Anwalt Herrn Höcker. (8/10)
Angermayer war über ein Investment-Vehikel bei Abcellera eingestiegen, die bei Entwicklung und Vermarktung der Corona-Medizin mit Eli Lilly kooperierte. Abcellera profitierte hierbei von Erfolgsprämien, Zahlungen und Beteiligungen an den Netto-Einnahmen des Konzerns. (6/10)
July 23, 2025 at 9:02 AM
Angermayer war über ein Investment-Vehikel bei Abcellera eingestiegen, die bei Entwicklung und Vermarktung der Corona-Medizin mit Eli Lilly kooperierte. Abcellera profitierte hierbei von Erfolgsprämien, Zahlungen und Beteiligungen an den Netto-Einnahmen des Konzerns. (6/10)
Spannende Infos über das milliardenschwere Netzwerk des J. Spahn. Zitat:
"Zwei Tage nach der Ankündigung der Bestellung des Bundesgesundheitsministeriums erreichte die Abcellera ihr Fünf-Jahres-Hoch und einen märchenhaften Wert von 16 Milliarden."
correctiv.org/aktuelles/ge...
"Zwei Tage nach der Ankündigung der Bestellung des Bundesgesundheitsministeriums erreichte die Abcellera ihr Fünf-Jahres-Hoch und einen märchenhaften Wert von 16 Milliarden."
correctiv.org/aktuelles/ge...
Netzwerk mit Nebenwirkungen: Jens Spahn und der Milliardär
Christan Angermayer gilt als Freund von Jens Spahn – und offenbar profitierte er als Investor von einer Großbestellung der Bundesregierung.
correctiv.org
July 23, 2025 at 1:29 AM
Spannende Infos über das milliardenschwere Netzwerk des J. Spahn. Zitat:
"Zwei Tage nach der Ankündigung der Bestellung des Bundesgesundheitsministeriums erreichte die Abcellera ihr Fünf-Jahres-Hoch und einen märchenhaften Wert von 16 Milliarden."
correctiv.org/aktuelles/ge...
"Zwei Tage nach der Ankündigung der Bestellung des Bundesgesundheitsministeriums erreichte die Abcellera ihr Fünf-Jahres-Hoch und einen märchenhaften Wert von 16 Milliarden."
correctiv.org/aktuelles/ge...